EDN1 and metastatic colorectal cancer: In addition, in their paper about plasma ET-1 levels before and after systemic treatment of bevacizumab for patients with metastatic colorectal cancer, Dirican et al. [21] found a significant decrease in serum ET-1 levels after treatment with bevacizumab.